Abstract
Prophylactic mupirocin for peritoneal catheter exit sites reduces exit site infection (ESI) risk but engenders antibiotic resistance. We present early interim safety analysis of an open-label randomized study comparing polyhexamethylene biguanide (PHMB) and mupirocin. A total of 106 patients randomized to 53 in each group were followed up for a mean of 12.68 months per patient. On safety analysis, the PHMB group had a significantly greater ESI rate than the mupirocin group (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.09 to 0.80), leading to discontinuation of the trial.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Anti-Infective Agents, Local / therapeutic use*
-
Biguanides / therapeutic use*
-
Catheters, Indwelling / adverse effects
-
Catheters, Indwelling / microbiology
-
Early Termination of Clinical Trials
-
Female
-
Humans
-
Male
-
Middle Aged
-
Mupirocin / therapeutic use*
-
Peritoneal Dialysis / adverse effects*
-
Prospective Studies
-
Pseudomonas Infections / etiology
-
Pseudomonas Infections / mortality
-
Pseudomonas Infections / prevention & control*
-
Staphylococcal Infections / etiology
-
Staphylococcal Infections / mortality
-
Staphylococcal Infections / prevention & control*
-
Survival Analysis
Substances
-
Anti-Bacterial Agents
-
Anti-Infective Agents, Local
-
Biguanides
-
polihexanide
-
Mupirocin